| Dr Michael J Eddy, MD | |
|
3520 E 15th St, Suite 200, Loveland, CO 80538-8938 | |
| (970) 669-9100 | |
| (970) 669-0400 |
| Full Name | Dr Michael J Eddy |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 28 Years |
| Location | 3520 E 15th St, Loveland, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386757508 | NPI | - | NPPES |
| 136739100 | Medicaid | WY | |
| 29939232 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 40112 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Of The Rockies | Loveland, CO | Hospital |
| Poudre Valley Hospital | Fort collins, CO | Hospital |
| Estes Park Medical Center | Estes park, CO | Hospital |
| Uchealth Greeley Hospital | Greeley, CO | Hospital |
| Longs Peak Hospital | Longmont, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
News Archive
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the Journal of Neurotrauma.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva's favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).
Synopsys is introducing a new automated segmentation tool for hips and knees, which will have the benefits.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists
› Verified 9 days ago
| Entity Name | Rocky Mountain Lithotripter Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134202435 PECOS PAC ID: 5395737985 Enrollment ID: O20040401001756 |
News Archive
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the Journal of Neurotrauma.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva's favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).
Synopsys is introducing a new automated segmentation tool for hips and knees, which will have the benefits.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists
› Verified 9 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the Journal of Neurotrauma.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva's favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).
Synopsys is introducing a new automated segmentation tool for hips and knees, which will have the benefits.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Eddy, MD 3520 E 15th St, Suite 200, Loveland, CO 80538-8938 Ph: (970) 669-9100 | Dr Michael J Eddy, MD 3520 E 15th St, Suite 200, Loveland, CO 80538-8938 Ph: (970) 669-9100 |
News Archive
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the Journal of Neurotrauma.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva's favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).
Synopsys is introducing a new automated segmentation tool for hips and knees, which will have the benefits.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists
› Verified 9 days ago
Dr. George H Phillips, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2500 Rocky Mountain Ave Ste 2200, Loveland, CO 80538 Phone: 970-669-9100 Fax: 970-669-0400 | |
Kurt Strom, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1813 Cheyenne Ave, Loveland, CO 80538 Phone: 970-203-2475 Fax: 970-203-2476 | |
Dr. John Michael Paddack, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1813 Cheyenne Ave, Loveland, CO 80538 Phone: 970-203-2475 Fax: 970-203-2476 | |
Dr. Gary R Goodman, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 3520 E 15th St, Suite 200, Loveland, CO 80538 Phone: 970-669-9100 Fax: 970-669-0440 |